The global head and neck squamous cell carcinoma market is anticipated to grow at a robust CAGR of around 7% to 9% during the forecast period from 2022 and 2032. Growth of the market is attributed to the increasing prevalence of head and neck cancer worldwide.
| Report Attribute | Details |
| Head and Neck Squamous Cell Carcinoma Market Projected Growth Rate (2022-2032) | 7% - 9% CAGR |
Head and neck squamous cell carcinoma is a group of cancers that develop in the mucous membranes of nose (nasal cavity and paranasal sinuses), mouth (oral cavity) and throat (oropharynx, larynx, hypopharynx). The condition often leads to serious symptoms such as abnormal patches or open sores in mouth and throat, unusual pain and bleeding of mouth, and breathing difficulties. Moreover, if it remains untreated, it can also spread to other body parts like lungs or lymph nodes and can be fatal.
During the last few years there has been a drastic upsurge in the cases of head and neck squamous cell carcinoma. According to a report published by the World Health Organization (WHO), more than 550,000 cases of head and neck cancers are reported annually while as around 300,000 deaths occur due to these cancers. In order to tackle this global burden, various cancer treatments such as chemotherapy and radiotherapy are being opted by people. This is providing a major impetus to the growth of head and neck squamous cell carcinoma market and the trend is likely to continue in the future.
Similarly, large amounts are being continuously spent by pharmaceutical giants, cancer associations and several other government organizations in research and development activities for the development of novel cancer treatment drugs. This will continue to generate lucrative growth opportunities within the head and neck squamous cell carcinoma market in the future.
Various cancer treatments drugs such as docetaxel, cisplatin and bleomycin are used alone or in combination for the treatment of head and neck squamous cell carcinoma. Availability of a variety of cancer treatment drugs is positively impacting the market growth.
In addition to this, increase in the number of specialty cancer centers across the globe will further generate growth prospects for head and neck squamous cell carcinoma market players in the foreseeable future.
High prevalence of head and neck cancers, increasing investments in research and development activities for introducing novel cancer drugs, rising government initiatives, growing popularity of combination therapy, and increasing healthcare awareness among people are some of the major factors driving the global head and neck squamous cell carcinoma market.
As the number of patients suffering from head and neck cancers continue to rise drastically, demand for innovative cancer treatments is witnessing huge upsurge throughout the world. People are opting for treatments like chemotherapy and radiotherapy to ease symptoms and improve the chances of survival. Rising adoption of these treatments to counter cancer will continue to act as a catalyst for the growth of head and neck squamous cell carcinoma market during the forecast period.
Various government and private organizations are continuously investing huge amounts for developing more advanced cancer treatments. These organizations are collaborating with research institutions and pharmaceutical companies to revolutionize the cancer treatment therapeutics.
Currently, large number of clinical trials are being conducted across different regions for introducing new cancer detection and treatment drugs. Driven by this, sales of head and neck cancer drugs are anticipated to rise at a healthy pace in the future.
Moreover, growing healthcare awareness among people coupled with increasing need for treating head and neck squamous cell carcinoma in its early stages is anticipated to create sales prospects for key market players during the assessment period.
There is no denying the fact that cancer treatments like radiotherapies and chemotherapies have become lifesaving treatment for cancer patients. However, the head and neck squamous cell carcinoma market is still facing various challenges that are restraining its growth.
Some of these factors are the high rate of complications, lack of early cancer detection, and high costs of head and neck squamous cell carcinoma cancer treatments. Moreover, lack of proper healthcare facilities across some developing and underdeveloped regions is also limiting the market growth.
North America was the largest market for head and neck squamous cell carcinoma in 2022 and the trend is expected to continue into the forecast period owing to the increasing research and development activities, highly established healthcare sector, increasing government funding towards cancer and heavy presence of leading market players.
Most of the cancer research is being conducted across North America countries such as the United States due to presence of advanced technologies, favorable regulations, and increasing funding by government and private organizations. These countries are home to some of the leading pharmaceutical companies and medical research organizations.
There has been a rapid surge in neck and mouth cancer cases in the U.S. during the last few years. The country witnessed around 54,000 new cases of oral cavity or oropharyngeal cancer and about 11, 230 deaths from oral cavity or oropharyngeal cancer in 2022 as per the American Cancer Society. Driven by this demand for cancer treatment drugs is slated to rise significantly during the forecast period.
According to Future Market Insights, the Asia Pacific head and neck squamous cell carcinoma market is poised to experience rapid growth, owing to the growing healthcare awareness, increasing government initiatives, rising patient pool, and expansion of cancer treatment hospitals and clinics.
Countries like India and China are witnessing huge upsurge in the cases of head and neck squamous cell carcinoma due to rapidly rising geriatric population, excessive betel quid chewing and high alcohol consumption. As a result, demand for cancer therapeutics is anticipated to rise at an exponential rate across these regions during the forecast period.
Similarly, rising awareness among people regarding head and neck cancers, their detection and treatment is positively impacting the market growth across Asia Pacific region and the trend is likely to continue in the future.
Some of the key participants present in the global head and neck squamous cell carcinoma market include Amgen, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., AbbVie, Eli Lilly, AstraZeneca, GlaxoSmithKline Plc, F. Hoffman-La Roche Ltd., Celegene Corporation among others.
These key players are vigorously investing in research and development activities for developing innovative cancer treatment drugs. Besides this, they have adopted growth strategies such as new product launches and approvals, increase in clinical trials, partnerships with research institutes and government organizations, launching awareness campaigns, and strengthening of distribution networks to gain a competitive edge in the market.
| Report Attribute | Details |
| Growth Rate | CAGR of 7% - 9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
Drug Type:
Distribution Channel:
Region:
FMI projects the global head and neck squamous cell carcinoma market to expand at a around 7% to 9% value CAGR through 2032.
Asia Pacific is expected to emerge as the most opportunistic market for head and neck squamous cell carcinoma drug manufacturers during the forecast period.
Amgen, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., AbbVie, Eli Lilly, AstraZeneca, GlaxoSmithKline Plc are some prominent head and neck squamous cell carcinoma manufacturers
Explore Similar Insights
Head and Neck Squamous Cell Carcinoma Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
